Ibrance
Breast, Advance Directives, Postmenopause + 3 more
Treatment
9 FDA approvals
6 Active Studies for Ibrance
Treatment for
Breast
What is Ibrance
Palbociclib
The Generic name of this drug
Treatment Summary
Palbociclib is a medication that works by affecting the cell cycle machinery. It is a type of cyclin-dependent kinase inhibitor that was developed by Pfizer Inc to treat certain types of breast cancer. Palbociclib was originally approved by the FDA in March 2015 for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer in women. The indications for Palbociclib were then expanded in 2019 to also include male patients based on evidence from clinical studies.
Ibrance
is the brand name
Ibrance Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Ibrance
Palbociclib
2015
12
Approved as Treatment by the FDA
Palbociclib, also known as Ibrance, is approved by the FDA for 9 uses including Metastatic Breast Cancer and refractory, metastatic Breast cancer .
Metastatic Breast Cancer
Used to treat Metastatic Breast Cancer in combination with Fulvestrant
refractory, metastatic Breast cancer
Used to treat refractory, metastatic Breast cancer in combination with Letrozole
Advanced Breast Cancer
Used to treat Advanced Breast Cancer in combination with Fulvestrant
Postmenopause
Used to treat Postmenopausal in combination with Fulvestrant
Metastatic Breast Cancer
Used to treat Metastatic Breast Cancer in combination with Fulvestrant
Advance Directives
Used to treat refractory, advanced Breast cancer in combination with Letrozole
prior endocrine therapy
Used to treat prior endocrine therapy in combination with Fulvestrant
Breast
Used to treat refractory, metastatic Breast cancer in combination with Letrozole
Breast
Used to treat Advanced Breast Cancer in combination with Fulvestrant
Effectiveness
How Ibrance Affects Patients
Palbociclib works by blocking cell growth and DNA replication in certain cancer cells, making them unable to reproduce and grow. This stops the cells from moving into the next stage of the cell cycle, which leads to them not being able to divide and reproduce. Studies on breast cancer cells have found that this drug is more effective in cells with high levels of a certain protein called RB1, low levels of a protein called CDKN2A, and medium levels of a protein called CCND1. In clinical trials, when taken with letrozole, palbociclib was able to increase the length of time without cancer
How Ibrance works in the body
Palbociclib is a drug that stops cancer cells from reproducing. It works by binding to an enzyme called CDK4/6, which controls the transition of cells from the G1 phase to the S phase. Palbociclib prevents this transition, thus halting the growth of cancer cells. It also stops the phosphorylation of proteins like retinoblastoma, which are involved in cell cycle progression. Palbociclib is effective against CDK4/6, but not other types of enzymes.
When to interrupt dosage
The degree of Ibrance is contingent upon the identified disorder, including Breast, Advance Directives and prior hormonal treatment. The quantity of dosage is determined by the technique of administration documented in the table below.
Condition
Dosage
Administration
Breast
125.0 mg, , 75.0 mg, 100.0 mg
, Oral, Capsule, Capsule - Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral
prior endocrine therapy
125.0 mg, , 75.0 mg, 100.0 mg
, Oral, Capsule, Capsule - Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral
Advance Directives
125.0 mg, , 75.0 mg, 100.0 mg
, Oral, Capsule, Capsule - Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral
Postmenopause
125.0 mg, , 75.0 mg, 100.0 mg
, Oral, Capsule, Capsule - Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral
Metastatic Breast Cancer
125.0 mg, , 75.0 mg, 100.0 mg
, Oral, Capsule, Capsule - Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral
Breast
125.0 mg, , 75.0 mg, 100.0 mg
, Oral, Capsule, Capsule - Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral
Warnings
There are 20 known major drug interactions with Ibrance.
Common Ibrance Drug Interactions
Drug Name
Risk Level
Description
9-(N-methyl-L-isoleucine)-cyclosporin A
Major
The risk or severity of adverse effects can be increased when Palbociclib is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Abemaciclib
Major
The serum concentration of Abemaciclib can be increased when it is combined with Palbociclib.
Acalabrutinib
Major
The metabolism of Acalabrutinib can be decreased when combined with Palbociclib.
Acteoside
Major
The risk or severity of adverse effects can be increased when Palbociclib is combined with Acteoside.
Alectinib
Major
The metabolism of Alectinib can be decreased when combined with Palbociclib.
Ibrance Toxicity & Overdose Risk
The lowest toxic dose of palbociclib taken orally is 100 mg/kg. If a person takes too much, only supportive measures can be taken. Additionally, palbociclib has been found to cause genetic damage and can harm unborn babies due to how it works. High doses of palbociclib have also been linked to an increased risk of brain tumors.
Ibrance Novel Uses: Which Conditions Have a Clinical Trial Featuring Ibrance?
At present, 94 active studies are assessing the potential of Ibrance to mitigate Postmenopausal symptoms, Breast Cancer and prior Endocrine Therapy.
Condition
Clinical Trials
Trial Phases
Metastatic Breast Cancer
1 Actively Recruiting
Phase 1, Phase 2
Breast
0 Actively Recruiting
Breast
0 Actively Recruiting
Postmenopause
5 Actively Recruiting
Phase 2, Not Applicable
Advance Directives
0 Actively Recruiting
prior endocrine therapy
0 Actively Recruiting
Ibrance Reviews: What are patients saying about Ibrance?
5
Patient Review
11/1/2016
Ibrance for Estrogen Receptor (ER)-Positive, HER2-Negative Postmenopausal Advanced Breast Cancer
5
Patient Review
6/26/2018
Ibrance for Estrogen Receptor (ER)-Positive, HER2-Negative Postmenopausal Advanced Breast Cancer
5
Patient Review
8/7/2020
Ibrance for Estrogen Receptor (ER)-Positive, HER2-Negative Postmenopausal Advanced Breast Cancer
5
Patient Review
11/29/2020
Ibrance for Estrogen Receptor (ER)-Positive, HER2-Negative Postmenopausal Advanced Breast Cancer
5
Patient Review
3/16/2019
Ibrance for malignant tumor or cancer
5
Patient Review
1/15/2018
Ibrance for Estrogen Receptor (ER)-Positive, HER2-Negative Postmenopausal Advanced Breast Cancer
5
Patient Review
5/22/2016
Ibrance for Estrogen Receptor (ER)-Positive, HER2-Negative Postmenopausal Advanced Breast Cancer
4.3
Patient Review
7/4/2017
Ibrance for Estrogen Receptor (ER)-Positive, HER2-Negative Postmenopausal Advanced Breast Cancer
4
Patient Review
7/19/2016
Ibrance for Estrogen Receptor (ER)-Positive, HER2-Negative Postmenopausal Advanced Breast Cancer
3.7
Patient Review
8/23/2017
Ibrance for Hormone Receptor (HR)-Positive, HER2-Negative Advanced Breast Cancer in Woman
2.7
Patient Review
5/26/2017
Ibrance for Estrogen Receptor (ER)-Positive, HER2-Negative Postmenopausal Advanced Breast Cancer
2.3
Patient Review
7/17/2017
Ibrance for Hormone Receptor (HR)-Positive, HER2-Negative Advanced Breast Cancer in Woman
1.3
Patient Review
7/13/2017
Ibrance for Estrogen Receptor (ER)-Positive, HER2-Negative Postmenopausal Advanced Breast Cancer
Patient Q&A Section about ibrance
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
What is the life expectancy on Ibrance?
"The median overall survival for women treated with Ibrance and Faslodex was 34.9 months, while the median overall survival for women treated with Faslodex alone was 28.0 months."
Answered by AI
What does Ibrance do to the body?
"IBRANCE interfere with the activity of the proteins CDK4 and CDK6, which are necessary for both healthy and cancer cells to divide. Hormonal therapy blocks or reduces the binding of hormones with hormone receptors to prevent the cells from growing and dividing."
Answered by AI
Is Ibrance like chemo?
"Bottom Line: Ibrance is not a traditional form of chemotherapy. It is an oral medication known as a targeted therapy, and is in the class of drugs known as CDK 4/6 inhibitors. It helps to slow cell growth in both cancer cells and healthy cells."
Answered by AI
What type of cancer does Ibrance treat?
"Ibrance is a cancer medication that works by inhibiting certain enzymes in the body. It is used in combination with an aromatase inhibitor, a type of hormonal therapy, to treat hormone-receptor-positive, HER2-negative breast cancer that has not been treated with hormonal therapy before. This medication is for use in postmenopausal women or men."
Answered by AI